At Belgian level, CHU de Liège coordinates the European multicenter registry which is in charge to evaluate current practices in terms of diagnosis and management of cardiac toxicity of breast cancer treatments (COT registry: EACVI/HFA Cardiac Oncology Toxicity Registry in Breast Cancer: EURObservational Research Program of the European Society of Cardiology).
In addition, our team evaluates new cardiac toxicity biomarkers (mRNA, BNP, ST2, Troponine, etc) in breast cancer as well as multi-modality imaging evaluations of cardiovascular complications of radiotherapy in adult.
Looking for clinical advice or support, or preparing for a clinical study? We will help you set up a cost-effective and time-efficient study! Get in touch with our experts [email@example.com].